BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 4205524)

  • 1. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of butalbital and phenobarbital pretreatment on antipyrine clearance in the rat.
    Tse FL; Chang T; Jaffe JM
    Arch Int Pharmacodyn Ther; 1986 Feb; 279(2):181-94. PubMed ID: 3963935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey.
    Branch RA; Shand DG; Nies AS
    J Pharmacol Exp Ther; 1973 Dec; 187(3):581-7. PubMed ID: 4203721
    [No Abstract]   [Full Text] [Related]  

  • 4. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.
    Le Couteur DG; Hickey H; Harvey PJ; Gready J; McLean AJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1553-8. PubMed ID: 10336552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
    Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
    J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenobarbital in the genetically obese Zucker rat. II. In vivo and in vitro assessments of microsomal enzyme induction.
    Brouwer KL; Kostenbauder HB; McNamara PJ; Blouin RA
    J Pharmacol Exp Ther; 1984 Dec; 231(3):654-9. PubMed ID: 6502519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic drug interactions.
    Nies AS; Shand DG; Branch RA
    Cardiovasc Clin; 1974; 6(2):43-53. PubMed ID: 4613462
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduced hepatic clearance of propranolol induced by chronic carbon tetrachloride treatment in rats.
    Iwamoto K; Watanabe J; Araki K; Satoh M; Deguchi N
    J Pharmacol Exp Ther; 1985 Aug; 234(2):470-5. PubMed ID: 4020680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the antipyrine test in laboratory animals. Studies in the dog and monkey.
    Vickers FF; Bowman TA; Dvorchik BH; Passananti GT; Hughes DM; Vesell ES
    Drug Metab Dispos; 1989; 17(2):160-5. PubMed ID: 2565205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chronic phenobarbital on verapamil disposition in humans.
    Rutledge DR; Pieper JA; Mirvis DM
    J Pharmacol Exp Ther; 1988 Jul; 246(1):7-13. PubMed ID: 3392664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol.
    Nies AS; Evans GH; Shand DG
    J Pharmacol Exp Ther; 1973 Mar; 184(3):716-20. PubMed ID: 4631471
    [No Abstract]   [Full Text] [Related]  

  • 15. Ranitidine alters antipyrine metabolism in control and phenobarbital-treated mice.
    Espiritu-Quiza MF; Skinner MH; Blaschke TF
    Methods Find Exp Clin Pharmacol; 1990 Nov; 12(9):631-6. PubMed ID: 2084458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of antipyrine in young rhesus monkeys (Macaca mulatta) with protein energy malnutrition.
    Sharma B; Mehta S; Nain CK; Mathur VS
    Drug Nutr Interact; 1985; 3(2):93-8. PubMed ID: 3921335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat.
    Chindavijak B; Belpaire FM; De Smet F; Bogaert MG
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1075-9. PubMed ID: 3418510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs.
    Shrewsbury RP
    Res Commun Chem Pathol Pharmacol; 1987 Mar; 55(3):375-96. PubMed ID: 3575876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat.
    Wood AJ; Villeneuve JP; Branch RA; Rogers LW; Shand DG
    Gastroenterology; 1979 Jun; 76(6):1358-62. PubMed ID: 437433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.